Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi-Dan Lin has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Ze-Guo Zhuo

    Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

    18 shared publications
  • Gang Li

    Department of Thoracic Surgery West China Hospital, Sichuan University 37 Guoxue 610041 Chengdu China

    14 shared publications
  • Gu-Ha Alai

    Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

    13 shared publications
  • Jun Luo

    Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

    13 shared publications
  • Xu Shen

    Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

    13 shared publications
  • Han-Yu Deng

    Sichuan Univ, West China Hosp, Dept Thorac Surg, 37 Guoxue Alley, Chengdu 610041, Peoples R China

    12 shared publications

Latest Publications

  • Open Access

    Advances in understanding the mechanisms underlying acquired resistance to third-generation tyrosine kinase inhibitors in non-small cell lung cancer

    by Gu-Ha A-Lai, Lian Li, Guangzhi Ma, Yong-Sheng Zhao, Peng Yao, Yi-Dan Lin

    Acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a formidable challenge in the treatment of non-small cell lung cancer (NSCLC). Despite the remarkable efficacy of these agents, resistance inevitably develops, typically within approximately 10 months of treatment initiation. This review elucidates the multifaceted mechanisms driving this resistance, broadly categorized into on-target EGFR-dependent alterations and off-target EGFR-independent bypass pathway activations. On-target mechanisms include the emergence of tertiary EGFR mutations, most notably C797S, which disrupts TKI binding. Off-target mechanisms encompass the activation of alternative signaling pathways such as MET and HER2/HER3 amplification, as well as histological transformations and complex changes within the tumor microenvironment. Furthermore, recent discoveries highlight the role of epigenetic dysregulation and metabolic reprogramming in fostering resistance. To counter this pervasive adaptability, advanced diagnostic methodologies, including liquid biopsy and high-resolution omics technologies, are crucial for real-time molecular profiling. The field is actively exploring emerging combination therapeutic strategies to circumvent these diverse resistance pathways, aiming to prolong clinical benefits and improve patient outcomes. The persistent emergence of resistance underscores that current targeted therapies, while revolutionary, are primarily disease-modifying rather than curative, necessitating continuous innovation to overcome the inherent biological challenge of tumor adaptability and heterogeneity.


  • Open Access

    A Novel Intra‐Operative Irrigation‐Drainage System for Robot‐Assisted Thoracoscopic Esophagogastric Layered Anastomosis: Preliminary Practice and Short‐Term Clinical Outcomes

    by Chuan Zhong, Lian Li, Zun Wang, Gu‐Ha A‐Lai, Yong‐Sheng Zhao, Yi‐Dan Lin

    Robot‐assisted thoracoscopic surgery facilitates the execution of intrathoracic hand‐sewn layered anastomosis during minimally invasive esophagectomy. However, challenges persist due to the complex technical demands inherent in this procedure. Patients who received robot‐assisted Ivor‐Lewis esophagectomy with intrathoracic hand‐sewn layered anastomosis for esophageal cancer were enrolled. A novel irrigation‐drainage auxiliary system designed for robot‐assisted thoracoscopic esophagectomy was introduced to optimize the execution of intrathoracic hand‐sewn layered anastomosis. The anastomosis time, operation time, postoperative complications, and postoperative hospital stay were evaluated. A total of 30 patients were enrolled, and the application of this system resulted in a median anastomosis time of 37 min (range: 28–65). None of the patients experienced postoperative anastomotic leakage or pleural cavity infection, indicating satisfactory short‐term safety and efficacy. The device improved operative efficiency by providing better exposure of the anastomotic region, enabling complete abdominal and thoracic drainage and freeing the assistant's hands for other tasks.

  • Open Access

    A circRNA promotes esophageal squamous cell carcinoma progression by inhibiting TRIM25-mediated degradation of IGF2BP family members

    by Shuangyan Tan, Yue Ming, Jiawei Guo, Wenrong Liu, Hulin Ma, Yu Liu, Zhijie Xu, A-Lai Gu-Ha, Lunzhi Dai, Yi-Dan Lin, et al.

    Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis and limited treatment options. While circular RNAs (circRNAs) are frequently dysregulated in ESCC, their functional roles and molecular mechanisms in tumor progression remain largely unexplored. We characterized circRNA using RT-PCR, Sanger sequencing, and fluorescent in situ hybridization. Gain- and loss-of-function studies in vitro and in vivo were performed to assess circRNA function. Molecular interactions were investigated via RNA pull-down assays coupled with mass spectrometry, electrophoretic mobility shift assays, co-immunoprecipitation, and immunoblot analysis. Clinical relevance was evaluated by RT-qPCR and immunohistochemistry in patient specimens. We identified circLNF, a novel circRNA derived from the long non-coding RNA FIRRE gene, which is significantly upregulated in ESCC. Functional assays demonstrated that circLNF promotes proliferative and migratory capacities in cultured cells and accelerates tumor progression and metastasis in animal models. Mechanistically, circLNF directly interacts with IGF2BP family proteins through their “CAUC” motifs, protecting them from TRIM25-mediated ubiquitination and proteasomal degradation. Importantly, circLNF expression positively correlated with IGF2BP1 protein levels in ESCC patient tissues, underscoring the clinical relevance of the circLNF-IGF2BP axis in ESCC progression. Our findings reveal an oncogenic role of circLNF in ESCC by inhibiting TRIM25-mediated proteasomal degradation of IGF2BP proteins and highlight circLNF as a potential therapeutic target for ESCC.


  • Open Access

    Racial disparities in the cause of death among patients with lung cancer in the United States

    by Yong-Sheng Zhao, Gu-Ha A-Lai, Hang Long, Chuan Zhong, Yi-Dan Lin

    Background: Racial disparities in lung cancer have existed in the United States (US) for many years. No studies have been conducted to elucidate the long-term trends of racial disparities in all-cause and cause-specific deaths in lung cancer patients. Our study aimed to explore trends and potential contributing factors of racial disparities. Methods: From the Surveillance, Epidemiology, and End Results (SEER) Program, we obtained the data of lung cancer patients diagnosed between 2000 and 2019, with follow-up until Dec 31, 2020. The cumulative mortality for Black, White, Asian or Pacific Islander (API), and American Indian or Alaska Native (AIAN) was calculated by diagnostic period and cause of death. By using Cox regression models, we determined the relative [hazard ratio (HR)] racial disparities and contributing factors. Results: The incidence and mortality rates during 2000–2019 for lung cancer decreased in all racial groups in men and women, especially for Black men. Despite a downward trend in the cumulative risk of death in racial groups, Black and API patients consistently had the highest and lowest mortality rates from 2000 to 2019, with adjusted HR of 1.14 and 0.83, respectively. The Black-White disparities in all-cause mortality narrowed over time, with adjusted HR of 1.18 [95% confidence interval (CI): 1.15–1.20] during 2000–2004 and 1.14 (95% CI: 1.11–1.16) during 2015–2019. Surgery and liver metastasis had the largest effect on Black-White disparities and API-White disparities, respectively. Conclusions: Our findings reveal persistent racial disparities among lung cancer patients, providing a theoretical basis for interventions to eliminate health disparities.


  • Open Access

    The Long Noncoding RNA LINC02820 Promotes Tumor Growth and Metastasis Through Regulating MYH9 Expression in Esophageal Squamous Cell Carcinoma

    by Xiaomin Xu, Xinting Mao, Wenrong Liu, Yue Ming, Tingting Zhang, Yang Yang, A‐Lai Gu‐Ha, Yi‐Dan Lin, Yong Peng

    Long noncoding RNAs (lncRNAs) play important roles in tumorigenesis, but their biological functions and mechanisms in esophageal squamous cell carcinoma (ESCC) remain poorly understood. In this study, we employed high‐throughput sequencing and bioinformatics analyses to identify the differentially expressed lncRNAs between ESCC tumors and adjacent normal tissues, among which LINC02820 is significantly upregulated in ESCC. Rapid amplification of cDNA ends assays determined the transcription initiation and termination sites of LINC02820, confirming it as a novel transcript variant localized in both the nucleus and cytoplasm of ESCC cells. Functional studies demonstrated that LINC02820 promotes cell proliferation and migration in vitro and enhances tumor growth and metastasis in vivo. Mechanistically, LINC02820 interacts with Myosin‐9 protein and prevent it from ubiquitination‐mediated proteasomal degradation. Additionally, the RNA‐binding protein insulin‐like growth factor 2 mRNA‐binding protein 2 binds to LINC02820 and increase its RNA stability in ESCC cells, thus upregulating LINC02820 expression. Therefore, these findings indicate LINC02820 as an oncogenic lncRNA in ESCC progression and suggest its potential as a therapeutic target.


  • Open Access

    Short-term outcomes of enhanced recovery after surgery protocol in robotic-assisted McKeown esophagectomy for esophageal cancer: a single-center retrospective cohort study

    by Xia Xu, Jiajun Xiong, Zhijie Xu, Zhi Hu, Guha Alai, Lulu Yu, Shaofeng Xia, Yidan Lin

    Background: This study aimed to evaluate the short-term outcomes of enhanced recovery after surgery (ERAS) protocol in perioperative robotic-assisted McKeown esophagectomy (RAME) among esophageal cancer patients.Methods: For this retrospective study, all patients who had undergone RAME with esophageal cancer using ERAS protocol and conventional management strategy at the surgery center of our hospital from February 2019 to March 2022 were performed for analysis.Results: A total of 211 patients were included. Compared to the conventional group, the ERAS group has shorter median operative time [207 (147.5-267.5) vs. 244 (183-305), Pvs. 4.54 ± 0.91), shorter duration of analgesia pump [2 (1-3) vs. 3 (2.5-5.5)], shorter postoperative hospital stay [(9 (6-47) vs. 11 (6-79)], shorter postoperative hospital stay within neoadjuvant treated patients [8 (7-43) vs. 13 (8-67], shorter postoperative ICU stay [1 (0-7) vs. 2 (0-15)], and less reoperation rate (7.6% vs. 16.8%). Furthermore, the overall complication rate was significantly lower in the ERAS group (26.1%) than in the conventional group (50.4%). Notably, the ERAS group had lower thoracic fluid drainage volume than the conventional group on postoperative 2-7 days (P<0.05).Conclusions: The application of ERAS protocol in esophageal cancer patients treated with RAME showed advantages of quick postoperative recovery in contrast to the conventional management strategy.


  • Open Access

    Role of Lower Esophageal Squamous Cell Carcinoma Margin Location on Abdominal Lymph Node Metastasis Risk

    by Xia Zhong, Xue-Hua Tu, Gu-Ha A-Lai, Ze-Guo Zhuo, Peng Yao, Ying Zhang, Zhi-Jie Xu, Yi-Dan Lin

    Background: Different sites of esophageal cancer are accompanied by different regional lymph node metastasis (LNM) risks. We aimed to investigate the impact of a lower tumor margin on abdominal LNM risk. Methods: We enrolled patients who underwent esophagectomy for esophageal squamous carcinoma (ESCC) from 2014 to 2017 in West China Hospital. Overall survival (OS) analysis was performed. We measured the distance between the lower tumor margin and esophagogastric junction (LED) with upper gastrointestinal contrast-enhanced X-ray (UGCXR). Multivariate logistic regression analysis and propensity score matching (PSM) were performed to explore the relationship between LED and the risk of abdominal LNM. Abdominal LNM risk in ESCC was stratified based on the location of the lower tumor margin. A model predicting abdominal LNM risk was constructed and presented with a nomogram. Results: The included patients had an abdominal LNM rate of 48.29%. In multivariate logistic regression analysis, LED was identified as a risk factor for abdominal LNM. Subgroup analysis of middle ESCC showed that patients with an LED less than 10 cm had a significantly higher rate of abdominal LNM than those with an LED greater than 10 cm. The abdominal LNM rate in middle ESCC patients with an LED less than 10 cm was 32.2%, while it was 35.1% in lower ESCC patients whose lower tumor margin did not invade the esophagogastric junction (EGJ), which was comparable after PSM. Conclusions: LED could help surgeons evaluate the risk of abdominal LNM preoperatively and better guide dissection of abdominal lymph nodes according to risk level.

  • Open Access

    Robot‐assisted thymectomy in large anterior mediastinal tumors: A comparative study with video‐assisted thymectomy and open surgery

    by Bin Jiang, Qun‐You Tan, Bo Deng, Long‐Yong Mei, Yi‐Dan Lin, Long‐Fei Zhu

    Background: The aim of this study was to evaluate the safety and effectiveness of robot‐assisted thymectomy (RAT) in large anterior mediastinal tumors (AMTs) (size ≥6 cm) compared with video‐assisted thymectomy (VAT) and open surgery.Methods: A total of 132 patients with large AMTs who underwent surgical resection from January 2016 to June 2022 were included in this study. A total of 61 patients underwent RAT, 36 patients underwent VAT and 35 patients underwent open surgery. Perioperative outcomes were compared.Results: There were no significant differences in tumor size (p = 0.141), or pathological types (p = 0.903). Compared with the open group, the RAT and VAT groups were associated with a shorter operation time (115.00 vs. 160.00, p = 0.012; 122.50 vs. 160.00, p = 0.071), and less blood loss (50.00 vs. 200.00, p < 0.001; 50.00 vs. 200.00, p < 0.001), respectively. The rate of conversion in the RAT group was similar to that in the VAT group (6.56% vs. 13.89%, p = 0.229). Concomitant resection was less frequently performed in the VAT group than in the RAT and open groups (5.56% vs. 31.15%, p = 0.040; 5.56% vs. 31.43%, p = 0.006). VAT patients had a lower drainage volume (365.00 vs. 700.00 and 910.00 mL, p < 0.001), shorter duration of chest tube (2.00 vs. 3.00 and 4.00, p < 0.001), and shorter hospital stay (5.00 vs. 6.00 and 7.00, p < 0.001) than the RAT and open groups. There was no 30‐day mortality in any group. No difference was seen in R0 resection rates (p = 0.846). The postoperative complication rates were similar among the three groups (p = 0.309). Total in‐hospital costs (66493.90 vs. 33581.05 and 42876.40, p < 0.001) were significantly higher in the RAT group.Conclusions: RAT is safe and effective for the resection of large AMTs compared to VAT and open surgery. Vascular resection in RAT is technically feasible. A long‐term follow‐up is required.